What are the challenges and limitations of Nusinersen treatment?
While Nusinersen has revolutionized the treatment of SMA, several challenges remain. The intrathecal administration can be challenging, especially in infants and patients with scoliosis or other spinal abnormalities. The high cost of Nusinersen is another significant barrier, although it is often covered by insurance or national health services in many countries. Additionally, while Nusinersen improves motor function and survival, it does not cure SMA, and ongoing research is needed to find more comprehensive treatments.
